Airway allergy causes alveolar macrophage death, profound alveolar disorganization and surfactant dysfunction

Front Immunol. 2023 May 10:14:1125984. doi: 10.3389/fimmu.2023.1125984. eCollection 2023.

Abstract

Respiratory disorders caused by allergy have been associated to bronchiolar inflammation leading to life-threatening airway narrowing. However, whether airway allergy causes alveolar dysfunction contributing to the pathology of allergic asthma remains unaddressed. To explore whether airway allergy causes alveolar dysfunction that might contribute to the pathology of allergic asthma, alveolar structural and functional alterations were analyzed during house dust mite (HDM)-induced airway allergy in mice, by flow cytometry, light and electron microscopy, monocyte transfer experiments, assessment of intra-alveolarly-located cells, analysis of alveolar macrophage regeneration in Cx3cr1 cre:R26-yfp chimeras, analysis of surfactant-associated proteins, and study of lung surfactant biophysical properties by captive bubble surfactometry. Our results demonstrate that HDM-induced airway allergic reactions caused severe alveolar dysfunction, leading to alveolar macrophage death, pneumocyte hypertrophy and surfactant dysfunction. SP-B/C proteins were reduced in allergic lung surfactant, that displayed a reduced efficiency to form surface-active films, increasing the risk of atelectasis. Original alveolar macrophages were replaced by monocyte-derived alveolar macrophages, that persisted at least two months after the resolution of allergy. Monocyte to alveolar macrophage transition occurred through an intermediate stage of pre-alveolar macrophage and was paralleled with translocation into the alveolar space, Siglec-F upregulation, and downregulation of CX3CR1. These data support that the severe respiratory disorders caused by asthmatic reactions not only result from bronchiolar inflammation, but additionally from alveolar dysfunction compromising an efficient gas exchange.

Keywords: airway allergy inflammation; allergic asthma; alveolar dysfunction; alveolar macrophages (AM); monocytes; pneumocyte hypertrophy; surfactant dysfunction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Asthma* / metabolism
  • Hypersensitivity* / complications
  • Inflammation / complications
  • Lung Diseases, Interstitial
  • Macrophages, Alveolar / metabolism
  • Mice
  • Pulmonary Surfactants*
  • Surface-Active Agents

Substances

  • Pulmonary Surfactants
  • Surface-Active Agents

Supplementary concepts

  • Surfactant Dysfunction

Grants and funding

This work was supported by the Ministerio de Economía y Competitividad (Grant SAF2015-69905 to CaA and Grant SAF2015-65307-R to CC), Ministerio de Ciencia e Innovación (Grants PGC2018-101899-B-100 and PID2021-122748OB-I00 to CaA, Grants RTI2018-094355‐B‐I00 and PID2021-123044OB-I00 to CC and Grant PID2021-124932OB-I00 to JP-G), and Comunidad de Madrid (Grant P2018/NMT4389 to JP-G).